Lilly (Eli) (LLY) Q2 2025 10-Q Quarterly Report
Lilly (Eli) (LLY) 10-Q quarterly report for Q2 2025, filed with SEC EDGAR on Aug 7, 2025 for the fiscal period ending Jun 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
Lilly (Eli) Q2 2025 10-Q Analysis
Management Discussion & Analysis
- • Cash and cash equivalents $3.38B as of June 30, 2025, up from $3.27B Dec 31, 2024
- • Total debt $39.90B, increased $6.26B from $33.64B at Dec 31, 2024, driven by $6.50B fixed-rate notes issuance
Risk Factors
- • Newly added risk: Collaboration amendment with Boehringer Ingelheim triggered one-time $370M Jardiance revenue benefit, affecting future revenue recognition
- • Most materially updated risk: Increased R&D expenses by 23% QoQ driven by expanded early and late-stage portfolio investments
Lilly (Eli) Q2 2025 Quarterly FinancialsXBRL
Revenue
$15.6B
▲ +37.6% YoY▲ +22.2% QoQ
Net Income
$5.7B
▲ +90.8% YoY▲ +105.1% QoQ
Net Margin
36.4%
▲ +1013bp YoY▲ +1471bp QoQ
Source: XBRL data from Lilly (Eli) Q2 2025 10-Q filing on SEC EDGAR. All figures in USD.
Other Lilly (Eli) Quarterly Reports
Get deeper insights on Lilly (Eli)
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.